"For the primary endpoint, all dose groups of BTX 1503 reduced the number of inflammatory lesions from baseline with the highest efficacy obtained for the 5% BTX 1503 QD group (-11.8 lesions). This corresponds to an average percent reduction of 40.54%. The combined vehicle group result was -11.3 lesions or an average percent reduction of 40.15%."
Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-7
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
0.005(1.79%) |
Mkt cap ! $444.9M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 28.3¢ | $794.4K | 2.742M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 588935 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 38510 | 3 |
View Market Depth
| Last trade - 14.10pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
28.5¢ |
Change
0.005 ( 1.86 %) |
||||
| Open | High | Low | Volume | ||
| 29.5¢ | 30.0¢ | 28.3¢ | 1197310 | ||
| Last updated 14.10pm 22/05/2024 ? | |||||
| BOT (ASX) Chart |